article thumbnail

Senate Dems reach draft deal to extend ACA premiums, lower drug costs

Healthcare Dive

The bill, part of a more than $300 billion package, extends enhanced ACA premiums and allows Medicare to negotiate select prescription drug prices starting in 2026.

ACA 222
article thumbnail

Health Provider News

Hall Render

Health Policy Commission still missing key document in Steward sale to Optum Local obesity drug developer lands deal worth up to $600M with Novo Nordisk Mass. Million CALIFORNIA California hospital dismisses CEO California physician pleads guilty to $2.5M million expansion ‘Very, very unusual.’ million expansion ‘Very, very unusual.’

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CMS Releases Guidance on Implementation of Rebate Programs for Certain Medicare Part B and Part D Drugs

Healthcare Law Blog

The Rebate Programs are administered as part of the prescription drug affordability provisions of the Inflation Reduction Act (the “IRA”), which is aimed at “lower[ing] out-of-pocket drug costs for people with Medicare and improv[ing] the sustainability of the Medicare program for current and future generations.” [1]

article thumbnail

Democrats Didn’t Achieve All Their Goals, but Inflation Reduction Act Makes Historic Medicare Changes

Kaiser Health News

First, it would give the federal government the ability to negotiate prices of some drugs purchased by Medicare beneficiaries, a tool that has long been opposed by the drug industry. Never before have we been able to negotiate prescription drug prices. Those prices would take effect in 2026.